Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VSTA to Address U.S. Pharmaceutical “Crisis” with Innovative Stem Cell-based Technology
Since its inception in 1998, the U.S. National Institutes of Health (NIH) has awarded biotech small-cap VistaGen Therapeutics with $11.3 million in R&D grants, including $2.3 million to support the company’s development of its Human Clinical Trials in a Test Tube™ platform, and $8.8 million for nonclinical and phase 1 clinical development of AV-101, the company’s lead small molecule drug candidate.
The company has also been awarded approximately $1.0 million of grant funding from the California Institute for Regenerative Medicine (CIRM) pertaining to R&D related to liver cells.
VSTA’s corporate development strategy hinges on strategic collaborations, which provides the company valuable access to cutting-edge expertise at a lower price than it would cost to develop the expertise internally. Ideal third-party collaborators include academic research institutions for stem cell research; CROs, which offer regulatory and drug development expertise; and medicinal chemistry companies that analyze drug rescue candidates and generate drug rescue variants.
Complementary to this strategy, VSTA in 2007 entered into a long-term sponsored stem cell R&D collaboration with University Health Network (UNH), one of the world’s largest research hospitals and an affiliate of world-renowned stem cell research facility, the McEwen Centre for Regenerative Medicine, for which VSTA co-founder Dr. Gordon Keller is the director. VSTA has also established several other strategic collaborations.
Leveraging these grants, collaborations and the expertise of Dr. Keller and his team of scientists, VSTA believes it has emerged as the first stem cell company focused primarily on stem cell technology-based drug rescue. Through a combination of licenses, patents, and trade secret laws, VSTA has secured intellectual property rights to the technology underlying its Human Clinical Trials in a Test Tube™. VSTA currently owns or has licensed 43 issued U.S. patents and 12 U.S. patent applications pertaining to its stem cell technologies.
VSTA says the U.S. pharmaceutical industry is facing a “drug discovery and development crisis,” signaled by the fact that while the pharmaceutical industry invested nearly $49 billion in R&D, a total of only 39 novel drugs were approved by the FDA. The hang-up centers on high costs of drug development and non-approval due to safety issues of the candidates.
VSTA aims to buck this trend by leveraging its human cells derived from its hPSC technology, which it considers superior to major toxicological testing systems that use animal cells and cellular assays based on transformed cell lines and human cadaver cells, which at best only approximate human biology. VSTA believes it can develop better medicine by using its technology to provide clinically relevant biological information about a new drug candidate early in the drug development process, before time and money are spent on clinical trials.
For more information, visit www.vistagen.com
NOTES PREPARED BY THE INDEPENDENT ACCOUNTING FIRM OF L.L.BRADFORD
During August 2012, a subsidiary (“Subsidiary”) of the Company entered into an Investors’ General Agreement and
Investment Platform Provider Business Agreement (hereafter the “Investor Agreement”). The Investor Agreement
describes the profit sharing between the investors and the Subsidiary and provides for weekly payment of those profits.
The agreement will be ongoing for five years
“It is important to note L.L. Bradford has received and reviewed each and every document supplied by the Company as to its authenticity in preparation of this comprehensive report. We have provided all requested documentary evidence to support the information prepared.
September 19, 2012
Hillard Herzog, CEO
Bergamo Acquisition Corp
Dear Mr. Herzog;
Included you will find the compiled financial statements of Bergamo Acquisition Corp as of and for the
period ended September 17, 2012. The financial statements were prepared based on discussions with
you along with reviewing information and agreements you provided. Thanks for giving us the
opportunity to serve Bergamo Acquisition Corporation. We look forward to working together in the
future.
Sincerely,
L.L. Bradford & Company, LLC
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
National Wealth International Ltd. has provided Bergamo Acquisition's wholly owned European subsidiary cashed-backed securities consisting of three separate tranches of 500 Million US Dollars issued through HSBC Bank, one of the world's largest banking and financial services organizations."
National Wealth International Ltd has a 1.5 Billion Dollars on Deposit at HSBC.
National Wealth and BGMO`S European subsidiary signed various investment agreements, National Wealth then made an investment and is sharing 50 percent of the profit with BGMO`S European subsidiary.
http://finance.yahoo.com/news/bergamo-acquisition-corp-signs-investment-165821767.html
FACT
Two questions all BGMO shareholders want answered.
1) How much money has BGMO made since September 17th
2) When will they have access to the money to close the VSTA and other acquisitions.
When we get the answer to question 2, BGMO will run like the proverbial scalded ape.
Timing is everything !!!!
It's not a matter of if BGMO will acquire approximately 70% of VSTA it just a matter of when.
We know the hold period of the of the initial profit of $88 million earned from the first tranche of investment funds of US $500 million will be up in a couple of months, but obviously BGMO and VSTA management believe the acquisition of VSTA will happen before then.
Quote:
In addition, the parties have agreed that no less than US $88 million, or its equivalent value in Euros, shall remain on deposit in the account of Bergamo Acquisition’s European subsidiary for a period of one year. This amount represents the initial profit earned from the first US $500 million cash-backed securities investments entered into between the parties previously, as set forth in Bergamo’s most recent consolidated financial report compiled by L.L. Bradford & Company LLC, a public accounting firm based in Nevada
Timing is everything
FACTS !!!!
Your wrong BGMO said they made $88,439,000 in net income (And L.L.Bradford[ )b]
For the period from January 1, 2012, through September 17, 2012, the company reported net income of $88,439,000, or $0.53 per share, on consolidated revenues of $283,952,000
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
Timing is everything !!!!!!
If you think the bank statement is a fraud, then why don't you get Herzog arrested !!!!
Oh yeah you tried and it didn't work, to bad so sad !!! ( because it's real )
Real as a heart attack !!!!!!
YOUR OPINIONS ARE WRONG AGAIN
So far the shareholders have only heard opinions please provide links to back up your opinion that this time is no different.
There is plenty of evidence that this is very different ( including a Bank Statement filed with OTC markets, and a CPA letter verifying the Bank Statement )
How BGMO Secured USD 1,000,000,000.00 CASH FUNDING
1. HSBC Bank Statement posted on OTC MARKETS Filings on Jan 29th, 2013.
2. HSBC BANK A/C Holder’s Name.
3. HSBC BANK A/C Number.
4. HSBC BANK A/C Authorized Signatory.
5. HSBC BANK A/C Bank Officer Name and Title
6. HSBC BANK A/C Bank Officer Bank E-Mail Address.
7. HSBC BANK A/C 2nd BANK OFFICER Title and E-Mail Address
8. HSBC BANK A/C Main Branch Phone Number.
CPA ADMITS IN THE 1ST Line of his Letter JAN 25TH, 2013).
“QUOTE BY CPA” I am writing this letter at your request to (“VARIFY”) certain
Information CPA received during his meeting on Jan 23rd, 2013 with the management of Bergamo Acquisition Corp.
“QUOTE BY CPA” This letter can serve as a summary of the documents only as
“ADDITIONAL” information included in the originals agreements.
“QUOTE BY CPA” BGMO AFFILIATE WAS GRANTED USD 1,000,000,000.00
National Wealth Ltd.
“QUOTE BY CPA” NATIONAL WEALTH LTD was granted USD 1,000,000,000.00
On Jan 18, 2013. For a period of three years.
“QUOTE BY CPA” The Documents reference CASH deposit with HSBC totaling
USD 1,000,000,000.00.
“QUOTE BY CPA” Pursuant to the documents through a bond power, Deed of Assignment,
Bond Power hereby referred to as “Grantee” is National Wealth Ltd, Affiliate of Bergamo Acquisition Corp.
a) CPA Letter Dated Sep 19th, 2012
b) CPA Letter Dated Jan 25th, 2013
c) OTCMARKETS Filings Section, Review Bank Statement
d) OTCMARKETS Filings Section, Review powers authorized to the
“Grantee” which is National Wealth Ltd affiliate of Bergamo Acquisition Corp
e) Bank Statement is posted showing CASH deposit of USD 1,000,000,000.00.
f) Press Release Issued on Jan 10th, 2013 and Press Release Dated Jan 31st, 2013.
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
!!!!!
I remember a wonderful photos from fat bank acct. a few month ago, count the zeros on the bank statement, and this is not a promise it's in the bank
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
Got Shares ( to bad everyone else sold ) NOT
Yeah I'm sure I said it it Aug, 2009 just before the stock ran to $ 1.19 and Sept. 2010 when it ran to .20
Only flippers and traders care where the stock trades from day to day, investors wait for the home run AGAIN !!!!!!!
Salute
YOU'RE WRONG AGAIN, HEARD IT ALL BEFORE ( YAWN )
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
BGMO is a once in a lifetime investment opportunity
Knock !! Knock !! Knock !!
Your right
The market already knows the answer to question #2..
Enjoy the ride !!!! ( if you have shares )
Timing is every thing !!!!
Salute
All profits generated from the use of the funds will be deposited in full to the bank of Bergamo’s European subsidiary company. These profits will be divided equally between National Wealth International Ltd. and the European subsidiary company of Bergamo Acquisition pursuant to the profit-sharing agreement between the parties.
In addition, the parties have agreed that no less than US $88 million, or its equivalent value in Euros, shall remain on deposit in the account of Bergamo Acquisition’s European subsidiary for a period of one year. This amount represents the initial profit earned from the first US $500 million cash-backed securities investments entered into between the parties previously, as set forth in Bergamo’s most recent consolidated financial report compiled by L.L. Bradford & Company LLC, a public accounting firm based in Nevada.
http://bergamocorp.com/2013/01/bergamo-acquisition-corp-signs-investment-agreement/
Just Keeping Them Honest
FACTS !!!
YOUR OPINIONS ARE WRONG AGAIN
So far the shareholders have only heard opinions please provide links to back up your opinion that this time is no different.
There is plenty of evidence that this is very different ( including a Bank Statement filed with OTC markets, and a CPA letter verifying the Bank Statement )
How BGMO Secured USD 1,000,000,000.00 CASH FUNDING
1. HSBC Bank Statement posted on OTC MARKETS Filings on Jan 29th, 2013.
2. HSBC BANK A/C Holder’s Name.
3. HSBC BANK A/C Number.
4. HSBC BANK A/C Authorized Signatory.
5. HSBC BANK A/C Bank Officer Name and Title
6. HSBC BANK A/C Bank Officer Bank E-Mail Address.
7. HSBC BANK A/C 2nd BANK OFFICER Title and E-Mail Address
8. HSBC BANK A/C Main Branch Phone Number.
CPA ADMITS IN THE 1ST Line of his Letter JAN 25TH, 2013).
“QUOTE BY CPA” I am writing this letter at your request to (“VARIFY”) certain
Information CPA received during his meeting on Jan 23rd, 2013 with the management of Bergamo Acquisition Corp.
“QUOTE BY CPA” This letter can serve as a summary of the documents only as
“ADDITIONAL” information included in the originals agreements.
“QUOTE BY CPA” BGMO AFFILIATE WAS GRANTED USD 1,000,000,000.00
National Wealth Ltd.
“QUOTE BY CPA” NATIONAL WEALTH LTD was granted USD 1,000,000,000.00
On Jan 18, 2013. For a period of three years.
“QUOTE BY CPA” The Documents reference CASH deposit with HSBC totaling
USD 1,000,000,000.00.
“QUOTE BY CPA” Pursuant to the documents through a bond power, Deed of Assignment,
Bond Power hereby referred to as “Grantee” is National Wealth Ltd, Affiliate of Bergamo Acquisition Corp.
a) CPA Letter Dated Sep 19th, 2012
b) CPA Letter Dated Jan 25th, 2013
c) OTCMARKETS Filings Section, Review Bank Statement
d) OTCMARKETS Filings Section, Review powers authorized to the
“Grantee” which is National Wealth Ltd affiliate of Bergamo Acquisition Corp
e) Bank Statement is posted showing CASH deposit of USD 1,000,000,000.00.
f) Press Release Issued on Jan 10th, 2013 and Press Release Dated Jan 31st, 2013.
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
Has anyone checked out Shawn Singh`s and the rest of the prestigious management team`s bio on the VistaGen website. Singh had a career as a corporate finance attorney and is a member of the State Bar of California.
Shawn K. Singh has built and sold many very large Biotech and Pharmaceutical companies, that are listed on the NASDAQ Stock Exchange ( I believe Shawn Singh before I believe anyone on the internet )
Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing.
http://www.vistagen.com/?page_id=38
Timing is everything !!!!!
Two questions all BGMO shareholders want answered.
1) How much money has BGMO made since September 17th
2) When will they have access to the money to close the VSTA and other acquisitions.
When we get the answer to question 2, BGMO will run like the proverbial scalded ape.
Timing is everything !!!!
No is is just a matter of when, but thanks for posting all the latest pr`s for BGMO everyone should pay special attention to one`s dated September 20, 2012, January 10, 2013,January 30, 2013 and January 31, 2013 still waiting for your proof that any of them are not real. I choose to believe L.L.Bradford before anyone on the internet
http://markets.financialcontent.com/stocks/news/read/23338486/bergamo_acquisition_corp._provides_authenticated_documentation_to_confirm_bank_deposits
http://markets.financialcontent.com/stocks/news/read/23325995/l.l._bradford_letter_confirms_funding_reported_by_bergamo_acquisition_corp.
http://markets.financialcontent.com/stocks/news/read/23173371/bergamo_acquisition_corp._signs_investment_agreement
http://markets.financialcontent.com/stocks/news/read/22308652/bergamo_acquisition_updates_financials
It's not a matter of if BGMO will acquire approximately 70% of VSTA it just a matter of when.
We know the hold period of the of the initial profit of $88 million earned from the first tranche of investment funds of US $500 million will be up in a couple of months, but obviously BGMO and VSTA management believe the acquisition of VSTA will happen before then.
Quote:
In addition, the parties have agreed that no less than US $88 million, or its equivalent value in Euros, shall remain on deposit in the account of Bergamo Acquisition’s European subsidiary for a period of one year. This amount represents the initial profit earned from the first US $500 million cash-backed securities investments entered into between the parties previously, as set forth in Bergamo’s most recent consolidated financial report compiled by L.L. Bradford & Company LLC, a public accounting firm based in Nevada
Timing is everything
FACTS !!!!
You must have missed this PR today, and it is in English !!!!
Under the terms of the parties' April 2013 agreement, as amended, Autilion AG has committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013. The parties have amended their agreement, completed a first closing and scheduled additional closings to occur in July, August and September 2013.
Autilion AG is a private company, but VSTA is a fully reporting company !!!!
Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com
This is not alleged
Under the terms of the parties' April 2013 agreement, as amended, Autilion AG has committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013. The parties have amended their agreement, completed a first closing and scheduled additional closings to occur in July, August and September 2013.
Try reading the notes from L.L. Bradford
Note 1 – Nature of Business and Summary of Significant Accounting Policies
The Company is engaged in investing in financial instruments and companies worldwide. During May 2012, the
Company purchased 100% interest in a European entity for its investing strategies utilizing the EURO currency.
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
Try reading VSTA filings !!
Autilion AG is a Bergamo Acquisition Corp Subsidiary in Europe.
http://www.otcmarkets.com/stock/VSTA/filings
On April 8, 2013, VistaGen Therapeutics, Inc. (the “ Company ”) and On April 8, 2013, VistaGen Therapeutics, Inc. (the “ Company ”) and Autilion AG (the “ Purchaser ”) entered into a Securities
Purchase Agreement pursuant to which the Company has agreed to sell, and the Purchaser has agreed to purchase, 72.0 million shares of the
Company’s Common Stock, for $0.50 per share, on or before April 30, 2013 (the “ Financing ”). The Securities Purchase Agreement contains
standard representations and warranties and provides that closing is subject to usual and customary closing conditions. The Securities Purchase
Agreement also provides for the election of one designee of the Purchaser to the Company’s Board of Directors. (the “ Purchaser ”) entered into a Securities
Purchase Agreement pursuant to which the Company has agreed to sell, and the Purchaser has agreed to purchase, 72.0 million shares of the
Company’s Common Stock, for $0.50 per share, on or before April 30, 2013 (the “ Financing ”). The Securities Purchase Agreement contains
standard representations and warranties and provides that closing is subject to usual and customary closing conditions. The Securities Purchase
Agreement also provides for the election of one designee of the Purchaser to the Company’s Board of Directors.
On April 30, 2013, VistaGen Therapeutics, Inc. (the “ Company ”) and Bergamo Acquisition Corp. PTE LTD (“ Bergamo ”) entered
into an amendment (the “ Amendment ”) to the Securities Purchase Agreement (the “ Agreement ”), dated April 8, 2013, and assigned to
Bergamo pursuant to the terms of an Assignment and Assumption Agreement, dated April 12, 2013. The Amendment amends the scheduled
investment dates, so that the first closing shall occur on or before May 15, 2013 and the final closing shall occur on or before September 30,
2013, as more particularly set forth below:
The foregoing description of the Amendment does not purport to be complete, and is qualified in its entirety by reference to the text of
the Amendment, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
Investment Date Total Amount of Investment Total No. of Shares
On or before May 15, 2013 $1,000,000 2,000,000
On or before May 31, 2013 $2,000,000 4,000,000
On or before June 30, 2013 $8,250,000 16,500,000
On or before July 30, 2013 $8,250,000 16,500,000
On or before August 31, 2013 $8,250,000 16,500,000
On or before September 30, 2013 $8,250,000 16,500,000
VistaGen Provides Update on $36 Million Strategic Financing Agreement
Ticker Symbol: U:VSTA
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/28/13
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing agreement with Autilion AG.
Under the terms of the parties' April 2013 agreement, as amended, Autilion AG has committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013. The parties have amended their agreement, completed a first closing and scheduled additional closings to occur in July, August and September 2013. As noted previously, the self-placed strategic financing does not include warrants or investment banking fees.
Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."
About VistaGen Therapeutics
VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube?, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical or biotechnology companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to unexpected safety issues relating to the heart or liver or adverse drug-drug interactions. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.
VistaGen's small molecule prodrug candidate, AV-101, has successfully completed Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.
Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.
Cautionary Statement Regarding Forward-Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the satisfaction of certain conditions to closing the strategic financing referred to in this press release, the success of VistaGen's stem cell technology-based drug rescue, predictive toxicology and metabolism screening activities, further development of stem cell-based bioassay systems and cell therapies, clinical development and commercialization of AV-101 for neuropathic pain or any other disease or condition, its ability to enter into strategic predictive toxicology, metabolism screening, drug rescue and/or drug discovery, development and commercialization collaborations and/or licensing arrangements with respect to one or more drug rescue variants, regenerative cell therapies or AV-101, risks and uncertainties relating to the availability of substantial additional capital to support its research, drug rescue, development and commercialization activities, and the success of its research and development plans and strategies, including those plans and strategies related to any drug rescue variant or regenerative cell therapy identified and developed by VistaGen, or AV-101. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.
For more information:
Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com
Terry Thompson is a joke and that is not his real name, this loser is Hal Wolfe con man and SEC impersonator.
Time to put this loser in jail where he belongs !!!
Nothing to hide here just a shareholder !!
Impersonating a S.E.C. employee is a Federal criminal offence, BGMO lawyers and the S.E.C. are well aware of this con artist and his co-conspirators charades.
Anyone else who would like to report this con artist Terry Thompson to the S.E.C. for violations of the Federal criminal laws, follow the link below
Also Global Arena was not an Incorporated company in the year 2000 to 2005, this con artist should be reported to the S.E.C. by all shareholders.
http://www.linkedin.com/profile/view?id=231384327&authType=name&authToken=Aole&goback=%2Ewvp_*1_*1_*1&trk=wvmx_p
http://www.sec.gov/news/press/2009/2009-39.htm
http://law.onecle.com/michigan/750-michigan-penal-code/mcl-750-217c.html
BGMO is as real as a heart attack
The money is right where the accountant says it is
All self explanatory (but the spinsters like to twist)
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
HSBC USD 1,000,000,000,00
If you take your shoes off, you can count the ZEROs
Bank statement verified by L.L.Bradford
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
NOTES PREPARED BY THE INDEPENDENT ACCOUNTING FIRM OF L.L.BRADFORD
The Company is engaged in investing in financial instruments and companies worldwide. During May 2012, the
Company purchased 100% interest in a European entity for its investing strategies utilizing the EURO currency.
Note 2 – Investment in marketable securities
Investment in marketable securities consists of 2,132,157 shares of common stock in a publically traded company at a
cost of $1 million. During the period from January 1, 2012 through September 10, 2012, the Company recorded an
unrealized loss of $0.1 million. As of September 17, 2012, the estimated fair value of the shares was $0.9 million.
During August 2012, a Stock Purchase Agreement was entered into to purchase 60% of a Delaware corporation in
exchange for $7.5 million in order to effect the purchase of a majority control of the publically traded company noted in
the preceding paragraph. As of the date of these financials, the
Note 3 – Commitments and Contingencies
During September 2012, the Company entered into a settlement agreement to satisfy outstanding debt and accrued
interest carried on the Company’s financials at approximately $1.0 million. The Company had previously defended
against the penalties and interest but agreed to a total settlement of approximately $2.9 million. Accordingly, the
Company recorded settlement expense of $1.9 million.
During August 2012, a subsidiary (“Subsidiary”) of the Company entered into an Investors’ General Agreement and
Investment Platform Provider Business Agreement (hereafter the “Investor Agreement”). The Investor Agreement
describes the profit sharing between the investors and the Subsidiary and provides for weekly payment of those profits.
The agreement will be ongoing for five years.
Note 1 – Nature of Business and Summary of Significant Accounting Policies
The Company is engaged in investing in financial instruments and companies worldwide. During May 2012, the
Company purchased 100% interest in a European entity for its investing strategies utilizing the EURO currency.
Summary of Significant Accounting Policies
Basis of Presentation
These financial statements and related notes are presented in accordance with accounting principles generally accepted in
the United States. The Company’s fiscal year-end is December 31.
The Company’s reporting currency is the United States dollar (USD) and functional currency is the EURO. Foreign
currency assets and liabilities are translated into their U.S. dollar equivalents based on year end exchange rates. Revenue
and expense accounts are translated at average exchange rates. Aggregate exchange gains and losses arising from the
translation of foreign assets and liabilities are included in shareholders' equity as a component of comprehensive income.
Accumulated gain on foreign currency translation adjustment was
Cash and Cash Equivalents
Cash equivalents include money market accounts which have maturities of three months or less. For the purpose of the
statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to
be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value.
Revenue Recognition
Investments in Financial Instruments – The Company earns commissions based on returns from investments in financial
instruments. Revenues are recorded upon receipt of actual returns.
Costs include commissions or revenue sharing arrangements with other parties.
Fair Value of Financial Instruments
The Company’s financial instruments include cash, receivables, available-for-sale securities and due to related parties.
Management believes the fair values of these financial instruments approximate their carrying values due to their shortterm nature.
For the period from January 1, 2012, through September 17, 2012, the company reported net income of $88,439,000, or $0.53 per share, on consolidated revenues of $283,952,000.
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
Who says there isn't !!!!
The Billion dollar question is how much has BGMO made since Sept, 17th ?
YOU'RE WRONG AGAIN, HEARD IT ALL BEFORE
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
Two things every BGMO shareholder should do in the morning,take your 4.32 inch morning constitutional, then open the ipad and go to OTC markets and count the zeros on the bank statement.
HEHEHEHEHE
HSBC USD 1,000,000,000,00
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
It was proven by the Certified Public Accounting Firm of L.L. Bradford. ( no they are not a Government agency ) LOL !!!
What part of L.L. Bradford has reviewed and verified the Bank Statement do people not understand, or maybe it`s disgruntled past business associates just don`t want to understand.
B/S
All profits generated from the use of the funds will be deposited in full to the bank of Bergamo’s European subsidiary company. These profits will be divided equally between National Wealth International Ltd. and the European subsidiary company of Bergamo Acquisition pursuant to the profit-sharing agreement between the parties.
In addition, the parties have agreed that no less than US $88 million, or its equivalent value in Euros, shall remain on deposit in the account of Bergamo Acquisition’s European subsidiary for a period of one year. This amount represents the initial profit earned from the first US $500 million cash-backed securities investments entered into between the parties previously, as set forth in Bergamo’s most recent consolidated financial report compiled by L.L. Bradford & Company LLC, a public accounting firm based in Nevada.
Just Keeping Them Honest
FACTS !!!
It's not a matter of if BGMO will purchase 72% of VSTA it just a matter of when.
We know the hold period of the of the initial profit of $88 million earned from the first US $500 will be up in a few months, but obviously BGMO managaent believe the purchase of VSTA will happen before then.
VSTA VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue
VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue
Ticker Symbol: U:VSTA
Great news for BGMO
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/07/13
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, announced that its high-quality, human pluripotent stem cell-derived cardiomyocytes (heart cells) were used by collaboration partner Duke University to grow a revolutionary three-dimensional (3D) human heart muscle. An abstract of the original research article published in Biomaterials, an international journal covering the science and clinical application of biomaterials, can be found online at: http://www.sciencedirect.com/science/article/pii/S0142961213004705.
Researchers at Duke University combined VistaGen's human stem cell-derived heart cells with innovative tissue engineering and cardiac electrophysiology technologies to grow what is being called a "heart patch," which mimics the natural functions of native human heart tissue. This heart patch technology is being developed to aid in a better understanding of the biology critical to cardiac tissue engineering, for applications in regenerative cell therapy for heart disease, and as predictive in vitro assays for drug rescue and development.
H. Ralph Snodgrass, PhD, VistaGen's President and Chief Scientific Officer, stated, "The developed contractile forces and other functional properties of these cardiac tissues are remarkable and are significantly higher than any previous reports. The achievement of successfully growing a human heart muscle from cardiomyocytes derived from human pluripotent stem cells not only expands the scope of our drug rescue capabilities, but also reflects the advanced nature and potential of our collaboration with the skilled biomedical engineers at Duke Medical Center."
"VistaGen's human cardiomyocytes produced engineered cardiac tissues that exhibited structural and functional properties superior to those previously reported," said Dr. Nenad Bursac, Associate Professor in the Departments of Cardiology and Biomedical Engineering at Duke University. "This is the closest man-made approximation of natural human heart muscle to date."
Achieving this capability represents a significant breakthrough in heart cell-based therapies and in testing new medicines for potential heart toxicity and potential therapeutic benefits impacting heart disease. The following are among several key development points from the study:
The optimized 3D environment of a cardiac tissue patch yields advanced levels of structural and functional maturation of human cardiomyocytes that produce expected responses to drugs;
Human cardiomyocyte maturation in an optimized 3D patch environment is enhanced relative to that found in industry standard 2D cultures;
No genetic modifications were used to produce, purify, or mature cardiomyocytes suggesting potential for future therapeutic applications;
Cardiac tissue patches generated using VistaGen's cardiomyocytes exhibited 2.2-180 fold higher contractile force generation compared to previous studies;
Based on a force per cardiomyocyte metric, cardiac tissue engineering methodology that used VistaGen's cardiomyocytes exhibited 4-700-fold higher efficiency than previously reported; and
Cardiac tissue patches generated using VistaGen's cardiomyocytes exhibited velocities of electrical signal propagation 5-fold higher compared to previous reports in human engineered cardiac tissues.
The original research article also will be published in print in Biomaterials.
About VistaGen Therapeutics
VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube?, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.
VistaGen's small molecule prodrug candidate, AV-101, has completed Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.
Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.
About Dr. Bursac, Duke University
Dr. Bursac, Associate Professor in the Department of Biomedical Engineering and Faculty of Cardiology at Duke University, is a leader in the field of cardiac tissue engineering and cell-based therapies in which different cells, either alone or in combination with therapeutic molecules or biomaterials, can be transplanted into the human body to restore function of damaged or diseased organs. Dr. Bursac's research has additional applications in the fields of cardiac electrophysiology and development of microphysiological systems for in vitro toxicology studies and drug screening. Over the last five years, Dr. Bursac's lab has developed and validated novel bioengineered model systems and experimental tools that are providing a more detailed understanding of normal and abnormal heart and skeletal muscle development and function, the intricate processes of myogenesis and the potential of stem cell-based tissue engineering therapies for the treatment of different heart and skeletal muscle diseases, cardiac infarction and arrhythmias.
Cautionary Statement Regarding Forward-Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the success of VistaGen's stem cell technology-based drug rescue, predictive toxicology and metabolism screening activities, further development of stem cell-based bioassay systems, and potentially improved cell therapies, for human blood system disorders or other diseases or conditions, clinical development and commercialization of AV-101 for neuropathic pain or any other disease or condition, its ability to enter into strategic predictive toxicology, metabolism screening, drug rescue and/or drug discovery, development and commercialization collaborations and/or licensing arrangements with respect to one or more drug rescue variants, regenerative cell therapies or AV-101, risks and uncertainties relating to the availability of substantial additional capital to support its research, drug rescue, development and commercialization activities, and the success of its research and development plans and strategies, including those plans and strategies related to any drug rescue variant or cell therapy identified and developed by VistaGen, or AV-101. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.
For more information:
Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com
Mission Investor Relations
IR Communications
Atlanta, Georgia
www.MissionIR.com
404-941-8975
Investors@MissionIR.com
And here is the same con man impersonating a Canadian citizen, check out " People Also Viewed "
Terry Thompson is a joke with zero credibility, and everything this con man says should be taken with the proverbial grain of salt.
Time to report this impersonating con man to the S.E.C. and the FBI
Just Keeping Them Honest
http://www.linkedin.com/profile/view?id=181605021&authType=name&authToken=rIqF&invAcpt=64749603_I340008272_60&goback=%2Epiv_I407609638*46
http://www.sec.gov/answers/impersonators.htm
Tell it to the judge
Impersonating a S.E.C. employee is a Federal criminal offence, BGMO lawyers and the S.E.C. are well aware of this con artist and his co-conspirators charades.
Anyone else who would like to report this con artist Terry Thompson to the S.E.C. for violations of the Federal criminal laws, follow the link below
Also Global Arena was not an Incorporated company in the year 2000 to 2005, this con artist should be reported to the S.E.C. by all shareholders.
http://www.linkedin.com/profile/view?id=231384327&authType=name&authToken=Aole&goback=%2Ewvp_*1_*1_*1&trk=wvmx_p
http://www.sec.gov/news/press/2009/2009-39.htm
http://law.onecle.com/michigan/750-michigan-penal-code/mcl-750-217c.html
BGMO is as real as a heart attack
Just Keeping Them Honest
Value of VSTA is Seen in Pharmaceutical Disasters
The importance of the work being done at VistaGen Therapeutics, developers of stem-cell based bioassay early-warning systems for determining possible toxicity of drug candidates, can be seen in the clinical disasters occasionally experienced by major players in the pharmaceutical industry. A recent article (http://dtg.fm/v3V4) by Valorie Sands in Minyanville, an Internet-based financial media and publishing company, gives an idea of the risks pharmacy companies face, and the need for better and earlier testing.
The article points to the 2010 withdrawal by Pfizer of Thelin (sitaxentan), a medication for treating pulmonary arterial hypertension that had been approved for marketing in Europe, Canada, and Australia, and was undergoing final clinical trials in the U.S., when liver toxicity claimed two lives. In 2008, Pfizer had paid roughly $195 million in a cash tender offer to acquire Encysive Pharmaceuticals to get the drug, which had generated sales of over $44 million for Pfizer in the 9 months prior to its withdrawal.
Another example referred to in the article was a class of highly effective anticancer drugs called anthracycines. In spite of their effectiveness in the treatment of lung cancer, breast cancer, lymphomas, leukemias, and other types of cancers, the use of these drugs is now considerably limited due to the later discovery of significant cardiotoxicity associated with anthracycines.
Overall, toxicity issues end up affecting many new drugs, often late in testing, or even when they have made it all the way to market. The risk is not only to the physical health of patients, but also to the fiscal health of the companies that have invested hundreds of millions in a drug’s development. VistaGen proposes a solution to the problem through its unique Human Clinical Trials in a Test Tube stem cell based platform designed to provide superior heart and liver toxicity testing right in the laboratory, well before clinical trials or market exposure.
For additional information, visit www.VistaGen.com
http://bergamocorp.com/